Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
161 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015', provides an overview of the Retinitis Pigmentosa (Retinitis)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinitis Pigmentosa (Retinitis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Retinitis Pigmentosa (Retinitis) Overview 8 Therapeutics Development 9 Pipeline Products for Retinitis Pigmentosa (Retinitis) - Overview 9 Pipeline Products for Retinitis Pigmentosa (Retinitis) - Comparative Analysis 10 Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies 11 Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes 13 Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Retinitis Pigmentosa (Retinitis) - Products under Development by Companies 17 Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes 20 Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 21 Acucela Inc. 21 Amarantus Bioscience Holdings, Inc. 22 Applied Genetic Technologies Corporation 23 Asklepios BioPharmaceutical, Inc. 24 Caladrius Biosciences, Inc. 25 DNAVEC Corporation 26 Dompe Farmaceutici S.p.A. 27 Genable Technologies Limited 28 Genethon 29 GenSight Biologics SA 30 Grupo Ferrer Internacional, S.A. 31 InFlectis BioScience 32 International Stem Cell Corporation 33 Isis Pharmaceuticals, Inc. 34 Mimetogen Pharmaceuticals Inc. 35 Neurotech Pharmaceuticals, Inc. 36 Ocata Therapeutics, Inc. 37 Orphagen Pharmaceuticals, Inc. 38 QLT Inc. 39 RegenxBio Inc. 40 ReNeuron Group Plc 41 SanBio, Inc. 42 Sanofi 43 Shire Plc 44 Spark Therapeutics, Inc. 45 Sucampo Pharmaceuticals, Inc. 46 Sun Pharma Advanced Research Company Ltd. 47 Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 56 Drug Profiles 58 AMRS-001 - Drug Profile 58 Antibodies to Antagonize IL-6 for Retinitis - Drug Profile 61 BNP-RP - Drug Profile 62 CB-11 - Drug Profile 63 ECL-1 - Drug Profile 64 emixustat hydrochloride - Drug Profile 65 FIB-111 - Drug Profile 67 Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 68 Gene Therapy for Ocular Diseases - Drug Profile 69 Gene Therapy for Ophthalmology - Drug Profile 70 Gene Therapy for Retinitis Pigmentosa - Drug Profile 71 Gene Therapy for Retinitis Pigmentosa - Drug Profile 72 Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile 73 Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile 74 Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile 75 Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile 76 Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile 77 GS-030 - Drug Profile 78 GT-038 - Drug Profile 80 IFB-088 - Drug Profile 82 ISIS-RHO2.5Rx - Drug Profile 83 KIRA-6 - Drug Profile 84 NT-501 - Drug Profile 85 OCU-100 - Drug Profile 88 PRO-015 - Drug Profile 89 proinsulin human SR - Drug Profile 90 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 91 ReN-003 - Drug Profile 93 Retinal Progenitor Cells for Ophthalmological Disorders - Drug Profile 95 RGX-321 - Drug Profile 97 RST-001 - Drug Profile 98 SAR-421869 - Drug Profile 99 SB-623 - Drug Profile 101 SHP-630 - Drug Profile 103 Small Molecule for Retinitis Pigmentosa - Drug Profile 104 Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Drug Profile 105 Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 106 Small Molecules for Retinitis Pigmentosa - Drug Profile 107 Small Molecules for Retinitis Pigmentosa - Drug Profile 108 Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile 109 SPKRPE-65 - Drug Profile 110 Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa - Drug Profile 113 Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 115 Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 116 Stem Cell Therapy to Activate MFRP for Retinitis Pigmentosa - Drug Profile 117 unoprostone isopropyl - Drug Profile 118 zuretinol acetate - Drug Profile 120 Retinitis Pigmentosa (Retinitis) - Recent Pipeline Updates 122 Retinitis Pigmentosa (Retinitis) - Dormant Projects 145 Retinitis Pigmentosa (Retinitis) - Discontinued Products 146 Retinitis Pigmentosa (Retinitis) - Product Development Milestones 147 Featured News & Press Releases 147 Appendix 156 Methodology 156 Coverage 156 Secondary Research 156 Primary Research 156 Expert Panel Validation 156 Contact Us 156 Disclaimer 157
List of Tables
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2015 13 Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 16 Number of Products under Investigation by Universities/Institutes, H2 2015 17 Comparative Analysis by Late Stage Development, H2 2015 18 Comparative Analysis by Clinical Stage Development, H2 2015 19 Comparative Analysis by Early Stage Development, H2 2015 20 Products under Development by Companies, H2 2015 21 Products under Development by Companies, H2 2015 (Contd..1) 22 Products under Development by Companies, H2 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2015 24 Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc., H2 2015 25 Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015 26 Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corporation, H2 2015 27 Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015 28 Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences, Inc. , H2 2015 29 Retinitis Pigmentosa (Retinitis) - Pipeline by DNAVEC Corporation, H2 2015 30 Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici S.p.A., H2 2015 31 Retinitis Pigmentosa (Retinitis) - Pipeline by Genable Technologies Limited, H2 2015 32 Retinitis Pigmentosa (Retinitis) - Pipeline by Genethon, H2 2015 33 Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H2 2015 34 Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015 35 Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H2 2015 36 Retinitis Pigmentosa (Retinitis) - Pipeline by International Stem Cell Corporation, H2 2015 37 Retinitis Pigmentosa (Retinitis) - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 38 Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2015 39 Retinitis Pigmentosa (Retinitis) - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2015 40 Retinitis Pigmentosa (Retinitis) - Pipeline by Ocata Therapeutics, Inc., H2 2015 41 Retinitis Pigmentosa (Retinitis) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015 42 Retinitis Pigmentosa (Retinitis) - Pipeline by QLT Inc., H2 2015 43 Retinitis Pigmentosa (Retinitis) - Pipeline by RegenxBio Inc., H2 2015 44 Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H2 2015 45 Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio, Inc., H2 2015 46 Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2015 47 Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H2 2015 48 Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics, Inc., H2 2015 49 Retinitis Pigmentosa (Retinitis) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015 50 Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 51 Assessment by Monotherapy Products, H2 2015 52 Number of Products by Stage and Target, H2 2015 54 Number of Products by Stage and Mechanism of Action, H2 2015 56 Number of Products by Stage and Route of Administration, H2 2015 58 Number of Products by Stage and Molecule Type, H2 2015 60 Retinitis Pigmentosa (Retinitis) Therapeutics - Recent Pipeline Updates, H2 2015 125 Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2015 148 Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2015 149
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
